Rare Diseases and Orphan Drug Policy

The session on Rare Diseases and Orphan Drug Policy addresses the public health challenges associated with conditions that affect small patient populations but collectively impact millions worldwide. Rare diseases are often chronic, progressive, and life-threatening, with limited diagnostic tools and treatment options. Delayed diagnosis, fragmented care pathways, and high treatment costs place a significant burden on patients, families, and health systems. Epidemiological research and policy frameworks are essential for improving visibility, access, and equity for rare disease communities, making this topic increasingly prominent at major Public Health Conference platforms focused on inclusive health systems.

From a public health perspective, rare diseases require population-level strategies despite their low individual prevalence. Disease registries, surveillance systems, and standardized classification frameworks help quantify disease burden and inform planning. The application of orphan drug regulation supports the development and approval of therapies by providing incentives such as market exclusivity, accelerated review pathways, and research funding. Epidemiological data guide prioritization of conditions, assessment of unmet needs, and evaluation of policy impact across regions.

Orphan drug policies play a critical role in balancing innovation, affordability, and access. High development costs and limited markets often result in expensive therapies, creating challenges for reimbursement and sustainability. Public health economics and outcomes research inform pricing strategies, coverage decisions, and health technology assessments for orphan medicines. Population-level evidence supports equitable access models while ensuring responsible use of limited health resources. Integration of patient registries with clinical and outcomes data strengthens monitoring of safety, effectiveness, and long-term impact.

As scientific advances expand the pipeline of therapies for rare conditions, policy and governance frameworks must adapt. Genomics, precision medicine, and advanced diagnostics are reshaping rare disease identification and management, raising new regulatory and ethical considerations. Workforce development initiatives emphasize multidisciplinary care coordination, data sharing, and patient engagement. International collaboration supports harmonization of regulatory standards and cross-border research. By strengthening rare disease epidemiology and orphan drug policy through evidence-based approaches, public health systems can improve diagnosis, promote innovation, and ensure that individuals living with rare diseases are not left behind.